Thompson Peter A. sold $4K of SION (indirect holdings)

Thompson Peter A. sold 101 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at $44.49 on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thompson Peter A.
Published May 30, 2026, 1:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 30, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SION
Neutral
medium confidence
Mentioned
$SION
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIONNeutralLow
01

Why it matters

The disclosure may slightly influence sentiment, but it does not introduce new company-specific fundamentals (no clinical, regulatory, or financial update).

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 nature and small dollar amount suggest limited trading impact.

03

What to watch

Check whether there are other recent Form 4 filings (buys/sells) or changes in trading patterns; one isolated sale is often noise.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed May 29 for a May 27 insider sale

Background

This is an SEC Form 4 insider transaction for Sionna Therapeutics, disclosed as an open-market sale by a director under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$SIONNeutralMedium confidence
Context

Sionna Therapeutics director Peter A. Thompson sold 101 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Limited/short-lived impact; any reaction is likely sentiment-driven rather than fundamentals.

Evidence & confidence

The filing is a routine 10b5-1 sale with small share count ($4.5k) relative to holdings, providing disclosure rather than new operating information.

Market effects

Minimal—single-company insider disclosure without drug/clinical or financing updates.

None expected.

None expected.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan and is small, it may reflect liquidity/portfolio management rather than bearish expectations.

Key entities

  • Sionna Therapeutics, Inc.

    US-listed biotech whose director sold shares under a pre-arranged 10b5-1 plan.

  • Peter A. Thompson

    Director who executed the reported open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIONLowAI 8/10

Sionna Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary

Sionna Therapeutics reported a wider net loss of $32.42M in Q3 2026, up 59.9% YoY, due to increased R&D and administrative expenses. The company selected SION-451 + SION-2222 for its dual combination program but will not advance SION-719 after a failed trial. It reduced its workforce by 46% and expects its cash runway to extend into 2H 2029.

$SIONMed

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. Sionna Therapeutics Reports Third Quarter 2026 Financial Results Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027 Clinical and nonclinical data presented at 2026 NACFC support advance

$SIONMedAI 8/10

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Sionna Therapeutics (Nasdaq: SION) will present data at the 2026 North American Cystic Fibrosis Conference. The company reported post hoc analyses of the PreciSION CF trial, showing an 8.6 mmol/L sweat chloride reduction with SION-719. Sionna plans to advance SION-451 + SION-2222 into a Phase 2a trial in early 2027. Preclinical data suggests potential benefits for a broad CF population.

$SIONMed

RA CAPITAL MANAGEMENT, L.P. (Kolchinsky Peter, Shah Rajeev M.) sold $21.8M of SION (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 3,448,811 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at an average of $6.33 ($6.32–$7.46, $21.84M total) across 2 trades on 2026-09-17. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund, L.P. (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo